Strategic acquisition Labtec is now part of AdhexPharma after a 2023 acquisition, signaling strengthened Germany presence and potential access to broader European sales channels, regulatory support, and expanded customer networks for cross-selling transdermal and oral film solutions.

Integrated CDMO As a full service CDMO covering development to manufacturing, Labtec offers end‑to‑end drug delivery capabilities which can be leveraged to consolidate buyers’ vendor lists, shorten timelines, and reduce compliance risk for pharmaceutical partners seeking a single point of contact.

Dermal and oral focus Specialization in transdermal systems and oral films aligns with growing demand for convenient, patient-friendly delivery methods, presenting opportunities to upsell higher‑margin formulations and expand into niche therapeutic areas with protected IP.

Regulatory readiness Emphasize Labtec’s German‑made quality and full regulatory compliance to win prospects requiring robust quality systems, audits, and GMP credibility, particularly for international clients seeking reliable manufacturing partnerships.

Tech enablement Current tech stack (iCIMS, Power BI, HubSpot, etc.) supports scalable sales workflows and data-driven targeting; leverage these tools to identify leads, track prospects, and deliver customized value propositions for pharma companies seeking turnkey development to market solutions.